Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

March 30, 2006 10:18 ET

Holmes Herbs, Inc.: Research Contract for Merck Pharmaceuticals

SCOTTSDALE, ARIZONA--(CCNMatthews - March 30, 2006) - Holmes Herbs, Inc. (OTCBB:HMHB) announced today that its clinical research subsidiary, Qualia Clinical Service Inc. ("Qualia"), has been awarded a clinical research contract from Merck & Co., Inc.. The contract relates to research on a human papiloma virus study for an upcoming Vaccine.

"Merck has been committed to vaccine research and development for over a century," said Dr. Sohail Khattak, President/CEO of Qualia. "We are committed to working with Merck to promote the development of vaccines and medicines that make a significant difference in people's lives."

About Merck

Merck & Co., Inc. (NYSE:MRK) is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information